NCT04179890 - The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib | Biotech Hunter

Enrollment

462

Participants

Timeline

Start Date

December 17, 2019

Primary Completion Date

July 22, 2021

Study Completion Date

July 22, 2021

Conditions

Non-squamous, Non-Small Cell Lung Cancer

Interventions

DRUG

Afatinib (Gi(l)otrif®)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.

DRUG

Erlotinib (Tarceva®)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.

DRUG

Gefitinib (IRESSA®)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.

DRUG

Osimertinib (Tagrisso®)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.

DRUG

Afatinib (Gi(l)otrif®)

As first line therapy.

DRUG

Osimertinib (Tagrisso®)

In the case the T790M resistance mutation was developed (second line therapy).

Trial Locations (1)

Royal Marsden Hospital, London